Market Report Source

Overview

Nanotechnologies have already attracted over $3bn of global government funding as part of efforts to enhance a range of disciplines including pharmaceuticals, drug delivery and healthcare monitoring. Advances in nanomaterials, nanostructures and nanosystems are expected to drive the value of the global nanotechnology market to over a trillion dollars by 2015, but many companies are remaining cautious, preferring to monitor developments in academia prior to making substantial investments. Despite such trepidation, the pharma industry is beginning to adopt nanotools throughout the R&D process to facilitate the high throughput screening of drug repositories, the identification of new drug targets and biomarkers for preclinical and clinical studies and the development of diagnostics and imaging agents.

Nanotechnology is a new report published by Business Insights that provides a comprehensive review of nanotechnology and it’s role in the development of next-generation nanomedicines. The nanotools and detection systems currently driving nanotechnology are profiled and the applications of nanotechnologies within the R&D process are assessed. This report measures the impact of nanotechnologies currently being applied to target cancer, cardiovascular disease and CNS disorders and also explores the implementation strategies of leading pharmaceutical, healthcare and nanotechnology start-ups.

Some key findings from this report:

• Nano-enabled delivery systems are the fastest growing form of nanotechnology amongst major pharma companies, helping to improve the targeted delivery of old, existing and shelved products. However many companies remain cautious, choosing to monitor the progress of nanotechnology prior to making significant investments.
• Optical imaging tags will help to identify diseases earlier and may avoid the need for expensive, high tech laser-based equipment. Diagnostic imaging of this kind is being increasingly applied to animals in preclinical dosing studies.
• Regulatory authorities are supporting nanotechnologies that can improve the development of pharmaceuticals and diagnostic agents. Many regulatory policies are currently being reassessed to ensure innovation and safety when utilising nanotechnologies.
• Many governments are keen to apply nanotechnology across pharmaceuticals, drug delivery and healthcare monitoring in an effort to reduce R&D costs and enhance levels of productivity.
• Nanomaterials are being utilised to develop more sensitive and specific POC diagnostic and biocompatible implants. Nanowires and cantilever assay systems will expand the market by helping to shift diagnostic tests from central laboratories to point of diagnostics

Key issues examined by this report:

• Nanotech acquistions. The potential acquisition of nanotech companies and in-licensing technologies is becoming a popular trend amongst pharma companies who are keen to counter the effects of industrial consolidation and low productivity.
• Go/no-go decision-making. The application of nanotechnology in biomarker discovery has enhanced the identification and validation of novel biomarkers for use in the pre-clincal and clinical development process, helping companies to engage in go/no-go decision-making significantly earlier.
• Fast-evolving technology platform. Novel nanomaterials are being evaluated as nanostructures whilst others have potential as biocompatible and biodegradable medical coatings and implants. The evolution of nano-enabled delivery systems may provide targeted delivery solutions for approved and upcoming agents and also help to reposition shelved products.
• Disease diagnosis/treatment. New nanotools that enhance contrast agents and improve optical imaging are expected to contribute in the earlier stages of disease diagnosis, and the construction of electrical/thermal nanosensors and nanodevices will help to diagnose, monitor and treat a disease.

Key questions answered:

• What is the role of nanotechnology in preclinical and clinical drug development?
• Which new nanotools and nanomaterials are driving growth?
• How is biomarker harvesting being affected by nanotechnology?
• Which major companies are developing nano enabled delivery systems?
• How are new optical tagging agents aiding animal dosing studies in the clinical development of safety assessment candidates?
• Which nanotechnologies are driving innovation in POC diagnostics?
• How are companies incorporating nanotechnology into their R&D programmes?

Table of Contents

Executive summary
Nanotechnology: driving change in pharmaceutical R&D
Nanotechnology: drug research & development
Nanotechnology: nanoformulations & nanocarriers
Nanotechnology: diagnostics & imaging
Nanotechnology: therapeutic applications
Nanotechnology: regulations, patents and scientific publications
Nanotechnology: challenges, opportunities & future applications

Chapter 1 Driving change in pharmaceutical
R&D
Summary
Defining nanotechnology
Nanotechnology funding
Nanotechnology evolution
Nanotechnology in the pharma industry
Nanotechnology start-up companies
Nanotechnology in academia
Drivers of nanotechnology research
Report Outline

Chapter 2 Drug research & development
Summary
Introduction
Nanotechnology in drug discovery & development
Nanotools for drug discovery & development
Application of nanotools in drug discovery & development
Nanoscaffolding
Nanoarrays
BioForce Nanosciences
Nanogen
Nanotubes & nanosensors
Nano-Proprietary Inc
Carbon Nanotechnologies Inc
Nanowires & cantilevers
Microfluidic lab-on-a-chip
Caliper Life Sciences
Nanofluidic lab-on-a-chip
Quantum Dots
Evident Technologies
Biomarker Harvesting
Instruments for nanodetection and analysis
Atomic force microscopy
Surface Plasmon Resonance
Instruments for nanofabrication
Dip Pen Nanolithography (DPN)
Conclusions

Chapter 3 Nanoformulations & nanocarriers
Summary
Introduction
Leading companies in nanoformulations
Approved nanoformulations
Dendrimers
Liposomal formulations
Pegylated liposomal formulations
Nanocrystal formulations
Nanoparticle formulations
Developmental nanoformulations
Protein-stabilized liposomal formulations
Controlled-release liposomal formulations
New controlled-release nanoparticle and nanosphere formulations
Magnetic nanoparticle formulations
Novel nanomaterials for drug delivery
Nanobombs
Nanoshells
Nanotubes
Conclusions

Chapter 4 Diagnostics & imaging
Summary
Introduction
Nanoarrays
Cystalline nanoarrays
Nanodevices
Magnetic nanoparticles, nanocapsules and nanocells
Nanoparticle barcodes
Multifunctional nanoparticles and nanocells
Gold nanoparticles
Fluorescent nanoparticles
Fluorescent nanocrystals
Nanoscale contrast agents
Multiplex imaging agents/therapeutics
Conclusions

Chapter 5 Therapeutic applications
Summary
Introduction
Nanotechnology in cancer
Research
In Vivo imaging
Molecular imaging & diagnostics
Drug delivery
Cancer conclusions
Nanotechnology in cardiovascular disease
Therapeutic research
Molecular imaging & diagnostics
Tissue engineering & regenerative medicines
Medical devices
Drug delivery
Cardiovascular conclusions
Nanotechnology in CNS
Research & development
Diagnostics & imaging
Drug delivery
Neurodevices and nanowires
CNS conclusions
Overall conclusions

Chapter 6 Regulations, patents and scientific
publications
Summary
Nanotechnology Guidelines
Patentability and publications
Nanotechnology patents
Nanotechnology-based publications
Conclusions

Chapter 7 Challenges, opportunities and future
applications
Summary
Introduction
Challenges in adopting nanotechnology
Regulations
Legal, political and ethical issues
Public perception of nanotechnology
Multidisciplinary infrastructure
Intellectual property
Commerciality of existing nanotechnology and medicines
Opportunities for adopting nanotechnology
Product repositioning
New imaging agents for early disease detection
Point-of-care diagnostics
Personalized medicines
Implementing nanotechnology in the pharma industry
Competitive strategies
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis
Roche
Pfizer
Elan Corporation
Genentech
GE Healthcare
Siemens Medical Solutions
Abraxis BioSciences
pSividia Limited
StarPharma Holdings Ltd
Alliances & licensing
Future impact of nanotechnology on drug discovery & development

Chapter 8 Appendix
Glossary
Bibliography
Index
Endnotes

List of Figures
Figure 1.1: Nanometer scale
Figure 1.2: Top-down and bottom-up nanotechnology approach
Figure 1.3: Applications of nanotechnology
Figure 1.4: Global nanotechnology funding, 2003
Figure 1.5: Global nanotechnology market by 2015
Figure 1.6: Evolution of nanotechnology 2000-2020
Figure 1.7: Evolution of the nanotechnology market
Figure 1.8: Nanotechnology applications in the pharma industry
Figure 2.9: Nanotechnology innovating the R&D process
Figure 2.10: Applications of nanotechnologies in drug discovery & development
Figure 2.11: TEM of native collagen fibers and nanoscaffolding
Figure 2.12: Array of probes on nanoarray
Figure 2.13: Bead Nanoarrays from NanoVic
Figure 2.14: NanoChip® 400 System
Figure 2.15: Nanosensors for analyte detection
Figure 2.16: Nanowires and cantilevers for nanodetection and multiplexing
Figure 2.17: Scanning electron microscope image of a five-nozzle M3 emitter
Figure 2.18: Evolution of microfluidics and nanofluidics in the pharma industry
Figure 2.19: Nanoparticle bioconjugate harvesting platform
Figure 2.20: Schematic of ATM technology
Figure 2.21: AFM images measuring real-time cell activity
Figure 2.22: Schematic of SPR technology
Figure 2.23: Schematic of DPN technology and its applications
Figure 3.24: Nanoformulations driving drug delivery
Figure 3.25: Dendrimer structure
Figure 3.26: Dendrimer delivery platform
Figure 3.27: DauxoXome® liposomal formulation
Figure 3.28: Doxil® liposomal formulation versus non-liposomal formulation
Figure 3.29: Enhanced bioavailability and absorption rate with Nanocrystals technology
Figure 3.30: Abraxane nab technology – Photosphere
Figure 3.31: Micellar nanoparticles (MNP)
Figure 3.32: Controlled-release liposomal formulations
Figure 3.33: Fullerene structures A) C-60 and B) C-70
Figure 3.34: AuroLase™ treated mice versus sham treatment
Figure 3.35: Carbon nanotubes
Figure 4.36: Nanotechnologies advancing diagnostics and imaging
Figure 4.37: ViriChip™ Virus Detection Platform
Figure 4.38: S-layer technology platform
Figure 4.39: Sensation™ Virus Detection Platform
Figure 4.40: BioNanoChannel ™ Bacterial Detection Platform
Figure 4.41: Biobarcode assays for the detection of PSA
Figure 4.42: Biosensor biobarcode
Figure 4.43: Oxonica’s Nanoplex™ biotag and POC diagnostic
Figure 4.44: AuroVist™ microCT image
Figure 4.45: NanoStrings™ Nanoparticle Barcoding
Figure 4.46: Schematic of fluorescent A) lanthanide structure and B) lanthanide nanoparticles
Figure 4.47: QDot Nanocrystal Structure
Figure 4.48: TriLite™ Emission Spectra
Figure 4.49: Viral Capsids as imaging carriers
Figure 4.50: Multifunctional nanocarriers for detection, diagnosis and treatment
Figure 4.51: Nanotechnology improving molecular detection and diagnosis of cancer
Figure 5.52: Application of nanotechnology in cancer, cardiovascular and CNS disorders
Figure 5.53: Cyberkinetic’s brain gate
Figure 6.54: Federal regulators addressing different aspects of nanotechnology
Figure 6.55: Japanese Governmental System for Science & Technology
Figure 6.56: Worldwide nanopatents 1995-2003
Figure 6.57: Worldwide nanopatents by region of applicant and inventor
Figure 6.58: Worldwide nanoscientific publications per world region
Figure 6.59: Worldwide nanoscientific publications per country and subfield 1999-2004
Figure 7.60: Future impact of nanotools on pharmaceuticals and healthcare
Figure 7.61: Health care trends to 2020 – GlaxoSmithKline

List of Tables
Table 1.1: Leading nanotechnology start-up companies
Table 1.2: Leading nanotechnology institutes, forums and networking organizations
Table 2.3: Key attributes of PuraMatrix versus other ECMs
Table 2.4: Leading Lab-on-Chip (LOC) and microfluidic manufacturers
Table 2.5: Leading manufacturers of QDots
Table 2.6: Advantages of DPN versus other top-down and bottom-up fabrication technologies
Table 3.7: Approved nanoformulations
Table 3.8: Leading nanoformulation companies
Table 4.9: Leading diagnostics and imaging companies evaluating nanotechnology
Table 5.10: Nano-enabled delivery system for cancer therapeutics
Table 5.11: Approved & developmental cancer nanomedicines
Table 5.12: Nanotechnology application in cardiovascular devices
Table 5.13: Nano-enabled delivery system under evaluation for cardiovascular therapies
Table 5.14: Nano-enabled delivery system under evaluation for CNS therapies
Table 7.15: Recent alliances and licensing deals in nanotechnology